Oncopeptides AB (CHIX:ONCOS) Growth Rank: 0 (As of Jul. 29, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:ONCOS Oncopeptides AB CHIX:ONCOS
46 GF Score
Price kr1.72
GF Value kr5.80
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Oncopeptides AB Growth Rank?

Oncopeptides AB has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Oncopeptides AB Growth Rank Related Terms

CHIX:ONCOS
46GF Score
Oncopeptides AB CHIX:ONCOS
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Oncopeptides AB (CHIX:ONCOS) Overvalued in 2026?

Based on GuruFocus' analysis, Oncopeptides AB stock appears to be undervalued. The current stock price of kr1.72 is trading 70.3% below its estimated GF Value™ of kr5.80. GuruFocus considers Oncopeptides AB to be Possible Value Trap.

Key valuation signals for CHIX:ONCOS:

  • Growth Rank: 0
  • GF Value™: kr5.80 vs. price of kr1.72 (70.3% below fair value)
  • GF Score™: 46/100 with 3 warning signs

No single metric tells the full story. See the CHIX:ONCOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oncopeptides AB Business Description

Address Luntmakargatan 46, Stockholm, SWE, SE-111 37
Oncopeptides AB is a Swedish biotech company focusing on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company uses its proprietary Peptide Drug Conjugate platform to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It is a science-driven biotech company developing targeted therapies for hard-to-treat cancers, combining cutting-edge research, entrepreneurial spirit, and a deep commitment to improving patients' lives. Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East, Africa, and elsewhere. The company generates maximum revenue from Germany.
46GF Score

Get the complete analysis for CHIX:ONCOS

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.72
Price
kr5.80
GF Value